-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Oropharyngeal Cancer Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a...
-
Product Insights
Anal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Anal Cancer - Drugs In Development, 2023’, provides an overview of the Anal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hypopharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypopharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Hypopharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Rectal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Rectal Cancer - Drugs In Development, 2023’, provides an overview of the Rectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Oropharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Oropharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Oropharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Laryngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Laryngeal Cancer - Drugs In Development, 2023’, provides an overview of the Laryngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Laryngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
High-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘High-Grade Glioma - Drugs In Development, 2023’, provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
United States (US) Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2028
US Defense Market Report Overview The US defense budget was worth $818.8 billion in 2023, which was a 10.7% rise from the previous year. This is in response to the deteriorating global security environment such as the Russian invasion of Ukraine and continued tensions with China over territory in the South China Sea and wider Indo-Pacific. Numerous geo-strategic and domestic political imperatives continue to drive US expenditure as defense capabilities gain growing political importance. The country’s defense budget is expected to...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BMX-001 in Rectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMX-001 in Rectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMX-001 in Rectal Cancer Drug Details: BMX-001 is under development for...